Core Insights - BioLineRx Ltd. announced promising results from a Phase 1 clinical trial of motixafortide for mobilizing CD34+ hematopoietic stem cells in sickle cell disease, indicating potential for improved gene therapy access [1][2][4] Group 1: Clinical Trial Findings - The trial demonstrated that motixafortide, both alone and in combination with natalizumab, was safe and well-tolerated, with common adverse events being transient [3][4] - A median of 198 CD34+ cells/μl was mobilized with motixafortide alone, projecting the collection of 13.9 million HSCs in a single apheresis session [4] - In combination with natalizumab, a median of 231 CD34+ cells/μl was mobilized, projecting the collection of 18.6 million HSCs in a single session [4] Group 2: Comparison with Current Standards - Current gene therapies for sickle cell disease require 16.5 million and 22 million total CD34+ HSCs, with plerixafor being the standard mobilization agent, which often requires multiple attempts [5] - Patients previously mobilized with plerixafor experienced 2.8-fold greater HSC mobilization with motixafortide alone and 3.2-fold greater with the combination therapy [6] Group 3: Future Presentation and Research - An oral presentation detailing these findings will occur at the ASH 2024 Annual Meeting on December 7, 2024, in San Diego, California [1][6] - The trial is part of ongoing research to enhance treatment options for patients with sickle cell disease, with continued collaboration with Washington University [2][8]

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of Mobilization Matters, a digital resource for people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant ...

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2024 Financial Results Conference Call. [Operator Instructions]. Following managem ...

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host con ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants Conference Call Participants Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2024 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. I would now like to turn over the call to John Lacey, Head of Investor Relations and C ...

- Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University - - ...

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life- changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations ...

In the event the Company does not regain compliance by November 11, 2024, the Company may be eligible for an additional 180 days to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. The Comp ...

- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia  - TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Resear ...

-  Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program - TEL AVIV, Israel, April 10, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 millio ...